HPV IN ENT - COMPREHENSIVE 20-MARK ANSWER

(RGUHS MS/DNB Otorhinolaryngology Standard)

OUTLINE

1. Introduction & Virology
2. Classification of HPV types
3. HPV Disease Entities in ENT
   • A. Recurrent Respiratory Papillomatosis (RRP) - the core topic
   • B. HPV-associated Oropharyngeal Squamous Cell Carcinoma (HPV-OPSCC)
   • C. Inverted Papilloma of Nose/Sinuses
   • D. Oral/Oropharyngeal Squamous Papilloma
4. Pathogenesis (with diagram)
5. Clinical Features
6. Diagnosis
7. Staging
8. Management (with flowcharts)
9. Complications & Malignant Transformation
10. Recent Advances
11. Prevention & Vaccination

1. INTRODUCTION

• Genome: 8 kb double-stranded DNA; icosahedral capsid; no lipid envelope
• Gene products:
  • Early genes (E1-E7): regulate viral replication and oncogenesis
  • Late genes (L1, L2): encode capsid proteins
• Key oncogenes: E6 (degrades p53) and E7 (inactivates pRb/retinoblastoma protein) - critical for malignant transformation
• Over 200 genotypes identified; classified by tissue tropism and oncogenic potential

2. CLASSIFICATION OF HPV TYPES

┌────────────────────────────────────────────────────────────┐
│              HPV CLASSIFICATION IN ENT                      │
├─────────────────────┬──────────────────────────────────────┤
│   LOW-RISK (Non-    │   HIGH-RISK (Oncogenic)              │
│   Oncogenic)        │                                      │
├─────────────────────┼──────────────────────────────────────┤
│ HPV 6, 11           │ HPV 16 (most common in OPSCC)        │
│ - Laryngeal RRP     │ HPV 18, 31, 33, 45                   │
│ - Oral papilloma    │ - Oropharyngeal SCC                  │
│ - Condyloma         │ - Malignant degeneration of RRP      │
│   acuminatum        │ - Tonsillar carcinoma                │
├─────────────────────┼──────────────────────────────────────┤
│ HPV 11 > HPV 6 in   │ HPV 16 responsible for >85%         │
│ aggressive disease  │ of HPV-OPSCC cases                   │
└─────────────────────┴──────────────────────────────────────┘

3A. RECURRENT RESPIRATORY PAPILLOMATOSIS (RRP)

DEFINITION

EPIDEMIOLOGY

• First-born child
• Vaginal delivery
• Teenage mother with condylomata acuminata

PATHOGENESIS DIAGRAM

 ┌─────────────────────────────────────────────────────────┐
 │           PATHOGENESIS OF RRP                           │
 │                                                         │
 │  HPV 6/11 (low-risk type)                              │
 │        ↓ Infects basal keratinocytes                   │
 │        ↓ Episomal (non-integrating) DNA                │
 │                                                         │
 │  E6 protein → minor p53 degradation (incomplete)       │
 │  E7 protein → pRb perturbation (incomplete)            │
 │                                                         │
 │        ↓ Uncontrolled squamous proliferation           │
 │        ↓ (No full malignant transformation)            │
 │                                                         │
 │  VEGF↑ → Angiogenesis → Fibrovascular cores           │
 │        ↓                                               │
 │  PAPILLOMA FORMATION                                   │
 │  (finger-like projections, squamous lining)            │
 │                                                         │
 │  Sites: Larynx (90-95%), Trachea (rare),               │
 │         Bronchi, Oral cavity                            │
 │                                                         │
 │  Triggering factor (HPV-11) → MALIGNANT               │
 │  TRANSFORMATION in 1.6-4% cases                        │
 └─────────────────────────────────────────────────────────┘

PREFERRED SITES IN LARYNX

• Free edge of vocal cords (most common)
• Upper surface of ventricle
• Lower surface of epiglottis
• Subglottis (at the transition to trachea)

CLINICAL FEATURES

• Hoarseness (earliest and most common symptom)
• Biphasic stridor
• Chronic cough
• Dysphonia progressing to aphonia
• Respiratory distress (in severe cases)
• No fever, no pain (benign disease)

• Hoarseness (most common)
• Throat discomfort
• Single or fewer lesions
• Less likely to cause airway compromise

ENDOSCOPIC APPEARANCE

HISTOPATHOLOGY

• Squamous epithelium arranged in finger-like projections
• Fibrovascular cores in each papilla
• Koilocytes (balloon cells with perinuclear halo) - pathognomonic of HPV infection
• Acanthosis, parakeratosis
• No nuclear atypia in benign disease
• Basement membrane intact

3B. HPV-ASSOCIATED OROPHARYNGEAL CANCER (HPV-OPSCC)

OVERVIEW

DISTINCT PROFILE OF HPV-OPSCC vs HPV-NEGATIVE OPSCC

MOLECULAR ONCOGENESIS FLOWCHART

HPV 16 (High-risk type)
        ↓
  Infects tonsillar crypt epithelium (reticulated epithelium)
        ↓
  VIRAL DNA INTEGRATES into host genome
        ↓
  ┌────────────────────┬──────────────────────────┐
  │ E6 Oncoprotein     │ E7 Oncoprotein           │
  │ ↓ binds p53        │ ↓ binds pRb              │
  │ Ubiquitin-mediated │ pRb releases E2F         │
  │ proteolysis        │ transcription factor     │
  │ ↓ p53 degraded     │ ↓                        │
  │ No apoptosis       │ Uncontrolled cell cycle  │
  │                    │ (G1→S phase entry)       │
  └────────────────────┴──────────────────────────┘
             ↓
  Genomic instability + immortalization
             ↓
  MALIGNANT TRANSFORMATION
             ↓
  HPV-OPSCC (Tonsil/Base of Tongue)

p16 AS SURROGATE MARKER

• p16 (CDKN2A) is overexpressed when pRb is inactivated by HPV E7
• p16 immunohistochemistry (IHC) is the standard clinical test for HPV-associated cancer
• Sensitivity ~94%, highly cost-effective
• Duel test (p16 IHC + HPV ISH) used for definitive confirmation
• p16 positivity: strong diffuse nuclear+cytoplasmic staining in >70% of cells

3C. INVERTED PAPILLOMA (Sinonasal)

• Definition: Benign epithelial neoplasm of sinonasal tract with unique growth pattern - epithelium inverts into underlying stroma (endophytic growth)
• HPV association: HPV 6, 11 (low-risk); also HPV 16, 18 in malignant transformation cases
• Location: Lateral nasal wall, middle meatus, maxillary and ethmoid sinuses
• Malignant transformation: 5-15% (to SCC)
• Staging: Krouse classification (T1-T4) / Cannady staging
• Treatment: Endoscopic sinus surgery (medial maxillectomy); open surgery for extensive disease
• Key feature: High recurrence if incomplete resection

4. DIAGNOSIS

DIAGNOSTIC FLOWCHART FOR RRP

 HOARSENESS IN CHILD / ADULT
          ↓
 Indirect / Flexible Laryngoscopy
          ↓
 Papillomatous lesions on vocal cords?
       YES ↓              NO → Consider other causes
          ↓
 Microlaryngoscopy (Direct Laryngoscopy under GA)
          ↓
 Biopsy of papilloma
          ↓
 ┌────────────────────────────────────────────┐
 │ HISTOPATHOLOGY                             │
 │ • Acanthotic squamous epithelium           │
 │ • Fibrovascular cores                      │
 │ • Koilocytes (pathognomonic)               │
 │ • No invasion (benign)                     │
 └────────────────────────────────────────────┘
          ↓
 HPV Typing (PCR/ISH) - HPV 6 or 11?
          ↓
 Derkay-Coltrera Staging Score
 (severity scoring for extent of RRP)
          ↓
 Imaging (CT Chest) if tracheal/pulmonary spread suspected

DERKAY-COLTRERA STAGING (RRP Severity)

• Epiglottis, aryepiglottic folds, arytenoids, false cords, true cords, ventricles, subglottis, trachea
• Higher score = more extensive disease / greater surgical burden

DIAGNOSIS OF HPV-OPSCC

Neck mass (cystic) ± Throat symptoms
          ↓
 Fine Needle Aspiration Cytology (FNAC) of neck node
          ↓
 p16 IHC on FNAC specimen - positive?
          ↓
 PET-CT / MRI for primary site localization
          ↓
 Panendoscopy + Directed Biopsy
   (Tonsil/BOT even if not visible)
          ↓
 Histopathology:
   Non-keratinizing basaloid SCC
   p16 IHC: strong diffuse +ve
   HPV ISH / HPV PCR confirmation
          ↓
 AJCC 8th Edition Staging (HPV-positive)

5. STAGING - AJCC 8TH EDITION (2017)

IMPORTANT: HPV-OPSCC has a SEPARATE STAGING from HPV-negative tumors since AJCC 8th Edition

6. MANAGEMENT

A. MANAGEMENT OF RRP (LARYNGEAL PAPILLOMATOSIS)

1. Maintain airway patency
2. Voice preservation
3. Minimize the number of procedures
4. Prevent disease spread to trachea/lungs

SURGICAL MANAGEMENT FLOWCHART

 RRP DIAGNOSED (Juvenile or Adult)
              ↓
 ┌────────────────────────────────────────┐
 │ SURGICAL DEBULKING                     │
 │ Under Microlaryngoscopy + GA           │
 │                                        │
 │ Options:                               │
 │ 1. CO₂ Laser (most used)              │
 │ 2. KTP (532 nm) Laser - angiolytic    │
 │ 3. Microdebrider (preferred by many)  │
 │ 4. Cold steel (scissors/cup forceps)  │
 │ 5. Pulsed Dye Laser (585 nm)         │
 │ 6. Nd:YAG Laser                       │
 │ 7. Cryotherapy                        │
 └────────────────────────────────────────┘
              ↓
 Airway adequate?
       YES ↓              NO → Tracheostomy (last resort)
              ↓
 Maintenance: Office-based KTP/PDL angiolytic laser
              ↓
 + Adjuvant Medical Therapy (see below)
              ↓
 Surveillance every 1-3 months

B. ADJUVANT MEDICAL THERAPIES

C. MANAGEMENT OF HPV-OPSCC

HPV+ OPSCC CONFIRMED (p16+)
              ↓
 MULTIDISCIPLINARY TEAM DISCUSSION
              ↓
 ┌─────────────────┬──────────────────────────┐
 │ EARLY STAGE     │ LOCALLY ADVANCED         │
 │ (I-II, AJCC 8th)│ (III-IV, AJCC 8th)      │
 ├─────────────────┼──────────────────────────┤
 │ Trans-oral      │ Concurrent               │
 │ Robotic Surgery │ Chemoradiation           │
 │ (TORS) +/- RT   │ (CisPlatin + RT 70 Gy)  │
 │                 │                          │
 │ OR              │ OR TORS + RT             │
 │                 │ (De-escalation trials)   │
 │ Radiation alone │                          │
 └─────────────────┴──────────────────────────┘
              ↓
 DE-ESCALATION STRATEGIES (Active Trials)
 (Due to better prognosis of HPV+ disease)
 - Reduced radiation dose
 - Omission of chemotherapy
 - MC1675 RCT (Lancet Oncol 2025) [PMID 40907518]

7. MALIGNANT TRANSFORMATION

FACTORS INCREASING RISK OF MALIGNANT TRANSFORMATION IN RRP
        ↓
 ┌─────────────────────────────────────────────┐
 │ 1. HPV-11 type (more aggressive than HPV-6) │
 │ 2. History of smoking / tobacco use         │
 │ 3. Prior irradiation                        │
 │ 4. Immunocompromised state                  │
 │ 5. Multiple recurrences                     │
 │ 6. Distal spread to trachea/bronchi         │
 └─────────────────────────────────────────────┘
        ↓
 Incidence: 1.6% to 4% (Cummings Otolaryngology)
        ↓
 Transformed to: Squamous Cell Carcinoma

8. HPV IN OTHER ENT SITES

9. RECENT ADVANCES (2023-2026)

1. HPV Vaccine for RRP Treatment

• Quadrivalent HPV vaccine (Gardasil - HPV 6, 11, 16, 18) administered to existing RRP patients has shown reduced surgical interval requirement
• Corbin et al., 2026 (PMID 41618836): 19-year retrospective cohort study - HPV vaccine uptake associated with significantly reduced recurrence in juvenile-onset RRP
• Vaccine acts by generating antibody response even in already infected individuals

2. Bevacizumab (Anti-VEGF) - Game Changer in RRP

• Intralesional bevacizumab injection after KTP laser ablation reduces papilloma regrowth
• VEGF inhibition targets the angiogenesis critical for papilloma re-establishment
• Systematic review (Zagzoog et al., Eur Arch ORL, 2024 [PMID 37831132]): Meta-analysis shows both cidofovir and bevacizumab reduce surgical frequency; bevacizumab favored for safety profile

3. De-escalation of Treatment in HPV-OPSCC

• MC1675 Phase III RCT (Lancet Oncol, 2025 [PMID 40907518]): De-escalated adjuvant radiotherapy vs standard treatment for HPV-associated OPSCC - primary results support reduced radiation toxicity without compromising survival in carefully selected patients
• ASTRO 2024 Guidelines [PMID 39078350]: Risk-stratified RT dosing for HPV+ OPSCC

4. TORS (Trans-oral Robotic Surgery)

• Minimally invasive resection of base of tongue and tonsil tumors
• Reduced morbidity vs open approaches
• Enables de-escalation of post-operative radiation

5. Immunotherapy in Recurrent/Metastatic HNSCC

• INTERLINK-1 Phase III RCT (Clin Cancer Res, 2025 [PMID 40300079]): Monalizumab + cetuximab in R/M HNSCC
• Pembrolizumab (anti-PD-1) now standard first-line for R/M HNSCC (KEYNOTE-048)
• HPV+ tumors show higher CD8+ TIL density - may predict better immunotherapy response (PMID 39565979)

6. Novel Adjuvant Therapies for RRP

• Murono S., Auris Nasus Larynx, 2025 [PMID 40339519]: Comprehensive narrative review of current treatments including PD-1 inhibitors as emerging options for aggressive RRP
• Ramos et al., 2025 [PMID 40516276]: Novel pathogenesis insights - STAT3 signaling, microbiome interactions, and mTOR pathway inhibition as potential therapeutic targets

7. Office-Based KTP Laser

• Awake office procedures using KTP/pulsed dye laser under local anesthetic
• Avoids repeated general anesthesia
• Subepithelial bevacizumab injection in same sitting
• Paradigm shift from periodic theater-based debulking to maintenance office therapy

10. PREVENTION

HPV VACCINATION

• Gardasil 4 covers HPV 6 and 11 → prevents laryngeal RRP and oral papillomas
• Gardasil 9 covers HPV 16 and 18 → prevents HPV-OPSCC
• Vaccination before sexual debut provides maximal protection
• National Immunization Program - RGUHS recommendation: Gardasil 9 preferred

SUMMARY TABLE (20-Mark Quick Reference)

SOURCES

• Cummings Otolaryngology Head and Neck Surgery - Ch. 74 (Epidemiology of HPV-OPSCC), Ch. 90 (Oral papilloma), Ch. 97 (HPV testing/p16), Ch. 112 (Tracheal papillomatosis), Ch. 117 (Neck staging)
• Scott-Brown's Otorhinolaryngology HNS (Vol.1 & Vol.2) - Ch. 32 (JORRP), Ch. 51 (Contact endoscopy/Papilloma), Ch. 79 (Laryngeal papillomatosis management)
• K.J. Lee's Essential Otolaryngology - HPV+ OPSCC section
• Zagzoog et al. Eur Arch Otorhinolaryngol 2024 - [Cidofovir vs bevacizumab meta-analysis, PMID 37831132]
• Murono S. Auris Nasus Larynx 2025 - [RRP treatment review, PMID 40339519]
• Ramos et al. Auris Nasus Larynx 2025 - [RRP pathogenesis novel strategies, PMID 40516276]
• Ma et al. Lancet Oncol 2025 - [De-escalation RT RCT, PMID 40907518]
• Margalit et al. Pract Radiat Oncol 2024 - [ASTRO HPV+ OPSCC guideline, PMID 39078350]
• Corbin et al. Otolaryngol HNS 2026 - [HPV vaccine in JORRP, PMID 41618836]